The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: To what extent should the results be generalizable?

American Heart Journal

Volumn 145, Issue 4, 2003, Pages 595-601

  Gerschutz, Gregory P ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; STROKE; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

EID: 0037383662     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.180     Document Type: Article

References (35)

1. AHA. Heart and stroke statistical update. Available at: http://www. americanheart.org. Accessed December, 2001.
2. Libby P. Multiple mechanisms of thrombosis complicating atherosclerotic plaques. Clin Cardiol 2000;23(6 Suppl):VI-3-7.
3. Schafer AI. Antiplatelet therapy. Am J Med 1996;101:199-209.
4. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 1988;296:320-31.
5. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categaries of patients. BMJ 1994;308:81-106.
6. Topol EJ. The future of antiplatelet therapy: optimizing management in patients with acute coronary syndrome. Clin Cardiol 2000;23(6 Suppl):VI-23-8.
7. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-5.
8. Weiss E J, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996;334:1090-4.
9. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation 1999;100:1667-72.
10. Berger PB. Oral antiplatelet agents: aspirin, ticlopidine, clopidogrel, cilostazol, and the oral glycoprotein IIb/IIIa inhibitors. In: Topol E, editor. Acute coronary syndromes. 2nd ed. New York: Marcel Dekker; 2001. p. 453-97.
11. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002;39:9-14.
12. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-39.
13. Bhatt DL, Hirsch AT, Ringleb PA, et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000;140:67-73.
14. Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103:363-8.
15. Bhatt D, Marso S, Hirsch A, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625-8.
16. George BS, Voorhees WD, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasly: clinical and angiographic outcomes. J Am Coll Cardiol 1993;22:135-43.
17. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998;339:1665-71.
18. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anti-coagulation Versus Aspirin and Ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-603.
19. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
20. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999;34:1891-4.
21. Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999;34:1884-90.
22. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999;99:2364-6.
23. Jauhar R, Bergman G, Savino S, et al. Effectiveness of aspirin and clopidogrel combination therapy in coronary stenting. Am J Cardiol 1999;84:726-8.
24. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safely of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102:624-9.
25. Taniuchi M, Kurz HI, Lasala JM. Randomized comparison of ticlopidine and clopidgorel after intracoronary stent implantation in a broad patient population. Circulation 2001;104:539-43.
26. Muller C, Buttner HJ, Petersen J, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents. Circulation 2000;101:590-3.
27. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000;284:1549-58.
28. Chew DP, Bhatt DL, Sapp S, et al. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001;103:201-6.
29. CURE Trial Investigators. The Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000; 21:2033-41.
30. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
31. Mehta S, Yusuf S, Peters R, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
32. Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) trial. Circulation 2001;103:1403-9.
33. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001;88:672-4.
34. Yusuf S, Flather M, Pogue J, et al. Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. Lancet 1998;352:507-14.
35. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;288:2411-20.